obesity drug news today glp-1 october 2025 health pharma drugs Outlook for obesity in 2025: more GLP-1 Agonists Market Report 2025-2033,

P., Smith, A

Adene Sanchez/E+ via Getty Image Patient education tips for GLP-1, weight loss drug treatment Obesity treatment is not a one-and-done process

With many Americans not meeting activity recommendations, its even more crucial to make movement a priority

Furthermore, it was stated that clinicians must consider treating patients with T2D and NAFLD with PIO, GLP-1R agonists or sodium-glucose co-transporters 2 (SGLT2) inhibitors to reduce their significant cardiovascular risk

Other authors include Jungting Yu, K

Patients who switched to phentermine after losing at least 20 pounds while on the GLP-1 medication were most likely to regain weight one year after discontinuing their GLP-1 medication, with more than half regaining some or all their weight